Risk stratification in cardiac surgery is a relevant issue. Many mortality risk models are currently available for clinicians and institutions. They are used to assign a specific operative mortality risk to individuals, to provide internal comparisons between surgeons, and to contrast the hospital performance with external benchmarks. Internal models accounting for specific risk profiles of the patient population may perform better than externally developed models. However, whereas external models are generally developed using very large series, often including up to 10 000 patients, internal models often rely on a more limited patient population. When addressing elective patients, the mortality rate is low, and the number of events is limited, allowing few predictors to be included in the model. In this retrospective, observational study, we have developed and validated an operative mortality risk score based on only 3 predictors: age, creatinine value, and left ventricular ejection fraction. This score provided a level of accuracy similar to or better than the EuroSCORE and other mortality risk scores with a better clinical performance. The limited number of predictors included in the model allows its use in relatively limited patient series, with the possibility of an annual recalibration, therefore accounting for possible local changes in clinical practice and risk profile of the patient population.
In an attempt to identify genetic mutations that may cause atrioventricular septal defects, a large-scale candidate screen of genes involved in atrioventricular valve and septum (AVS) formation has been performed in patients with atrioventricular septal defects. By sequencing 32 candidate genes (selected for their role in AVS development from animal and cell culture studies), we identified 11 putative deleterious mutations in 10 different genes in patients with atrioventricular septal defects. Focusing on variations identified in the bone morphogenetic protein receptor, ALK2, we performed in vitro and in vivo functional analyses and demonstrated that a dominant-negative allele of ALK2 exists in a patient with a defect originating in the AVS. The functional evidence suggests that individuals possessing this dominant-negative allele have reduced bone morphogenetic protein signaling capacity, and considering the role of bone morphogenetic protein signaling in AVS development, it is likely to be deleterious to AVS formation. These findings may have implications for screening these genes, particularly ALK2, in instances when atrioventricular septal defects are suspected. See p 3062.
Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection
Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute Few population-based studies have provided a detailed comparison of clinical characteristics and survival of participants with symptomatic heart failure with preserved (HFPEF) versus reduced ejection fraction (HFREF). In this study, we examined risk factors, clinical onset characteristics, and outcomes of patients with HFPEF and HFREF in the Framingham Heart Study. We found that preexisting cardiovascular disease risk factors, including diabetes mellitus, smoking, and hypertension, commonly preceded the onset of both HFREF and HFPEF and that these preonset risk factors alone did not distinguish between HFPEF and HFREF. In contrast, clinical features at the time of acute heart failure onset differentiated between a preserved and a reduced ejection fraction. The major factors conferring increased odds of HFREF versus HFPEF included male sex, prior myocardial infarction, or coronary heart disease and left bundle-branch block. Survival was reduced in those with HFPEF and HFREF compared with controls without heart failure, and mortality was increased when coronary heart disease was the underlying cause in those with HFREF. These findings suggest that HFPEF and HFREF are partially distinct entities, with potentially different approaches to early detection and prevention. Characterization of heart failure by left ventricular ejection fraction and underlying disease cause enhances our knowledge of heart failure pathogenesis and prognosis and may lead to earlier identification of individuals at increased risk for heart failure and its dire consequences. See p 3070.
Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study
The impact of standard risk factors (male sex, age, systolic blood pressure, antihypertensive treatment, cholesterol levels, smoking, and diabetes mellitus) on 10-year risk of coronary or cardiovascular disease (CVD) has been studied extensively, and reliable algorithms exist for risk prediction. In the present investigation, we evaluated the impact of standard risk factors on CVD incidence on long-term follow-up (ie, over 30 years). Our observations suggest that standard risk factors remain highly predictive of CVD risk over a 30-year follow-up period and that their impact is substantial even if levels are not updated. We also quantified the impact of body mass index on 30-year risk of CVD and observed that its association with increased CVD risk is mediated partly through promoting higher levels of standard risk factors over a long-term follow-up. Additionally, we have formulated a 30-year CVD risk prediction algorithm that adjusts for the competing risk of death on long-term follow-up. Our observations suggest that different applications of 10-year risk prediction functions for estimating 30-year CVD risk may be suboptimal, especially when applied to younger women and men who have an adverse risk factor profile. We also have constructed a simple calculator for estimating 30-year risk of CVD that is based on standard risk factors (with and without knowledge of laboratory values) and that could be implemented easily in primary care settings. See p 3078.
Longitudinal Tracking of Left Ventricular Mass Over the Adult Life Course: Clinical Correlates of Short-and Long-Term Change in the Framingham Offspring Study
Clinically overt heart failure is the end point of a long disease continuum characterized by progressive structural and functional changes of the heart, a dynamic process referred to as cardiac remodeling. Considering the current burden of heart failure and the projected increase over the next 50 years, it is critical to understand factors that influence cardiac remodeling over the adult life course. Using longitudinal data from the Framingham Offspring cohort (up to 4 serial routine echocardiographic observations on each individ- . Women also displayed a greater increase in left ventricular mass with increasing body mass index (compared with men). Participants with optimal values of these cardiovascular risk factors experienced lesser increases in left ventricular mass over time. Analyses evaluating short-term (4-year) changes in left ventricular mass (2605 unique individuals providing 4494 observations) identified the same key determinants that influenced its long-term trajectory (ie, body mass index, sex, systolic blood pressure, antihypertensive treatment, and smoking). These observations are consistent with the notion that maintenance of optimal levels of these risk factors in young to midlife will reduce the burden of left ventricular hypertrophy, and possibly heart failure, in older age. See p 3085.
DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study
This was a randomized, placebo-controlled, phase II trial designed to evaluate the safety of and provide preliminary data on the potential efficacy of 3,5-diiodothyropropionic acid in patients with stable congestive heart failure. Although the trial was stopped early because of increased side effects at the dose we chose, the data do show beneficial hemodynamic effects of a thyroid hormone analog in the treatment of congestive heart failure. The use of a thyroid hormone analog to treat congestive heart failure is a new and different conceptual approach to the treatment of heart failure because the presumed mechanism of action of the thyroid hormone analog is to alter the molecular composition of the heart and vasculature. If the outcome in patients with congestive heart failure is to be improved, different approaches must be examined that include structural and molecular targets as opposed to attempts to achieve more and more neurohormonal blockade. See p 3093.
Comparison of Primary Percutaneous Coronary Intervention and Fibrinolytic Therapy in ST-Segment-Elevation Myocardial Infarction: Bayesian Hierarchical Meta-Analyses of Randomized Controlled Trials and Observational Studies
The American Heart Association Mission Lifeline recently recommended major reorganizations in the structures and processes involved in reperfusion therapy for acute myocardial infarction with ST-segment elevation. In view of the major investments required for these reorganizations, systematic reviews of randomized controlled trials (RCTs) and observational studies to compare primary percutaneous coronary intervention and fibrinolytic therapy in diverse patient populations and clinical contexts are particularly timely. Meta-analyses of both RCTs and observational studies are consistent in showing short-term reductions in mortality and reinfarction with primary percutaneous coronary intervention, attesting to the superiority of this reperfusion strategy. The smaller reductions in shortterm mortality and reinfarction with primary percutaneous coronary intervention reported in observational studies compared with RCTs may relate to confounding and selection bias, as well as less optimal application of primary percutaneous coronary intervention in the real world. The inconclusive evidence in observational studies for differences between the 2 reperfusion strategies in long-term mortality and reinfarction may be due to optimal long-term medical therapy and coronary intervention in the patients who received fibrinolytic therapy that may have attenuated the early benefits associated with primary percutaneous coronary intervention. The potential benefits of prehospital fibrinolysis could not be ascertained in this systematic review and may be better evaluated in large RCTs and observational studies. See p 3101.
Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non-ST-Elevation Myocardial Infarction
In this study of outcomes over a median follow-up period of 4 years among a contemporary cohort of patients undergoing cardiac catheterization for ST-elevation myocardial infarction (STEMI; nϭ1974) and non-STEMI (NSTEMI; nϭ2413) at an academic medical center, we compared mortality rates over restricted time intervals and the differential impact of early revascularization on mortality stratified by ST-elevation status. The long-term mortality rates of 29% and 45% for STEMI and NSTEMI, respectively, remain very similar to historical mortality rates among patients with Q-wave and non-Q-wave MI in the era before reperfusion and early invasive therapy, indicating a critical need to develop more efficacious treatment strategies for both types of MI. The adjusted mortality risk was greater for STEMI during the first 2 months (hazard ratio for STEMI versus NSTEMI, 1.85; 95% confidence interval, 1.45 to 2.38) but greater for NSTEMI after 2 months (hazard ratio for STEMI versus NSTEMI, 0.68; 95% confidence interval, 0.59 to 0.83). Compared with late or no revascularization, early revascularization was associated with a lower adjusted risk of long-term mortality for both STEMI (hazard ratio, 0.73; 95% confidence interval, 0.58 to 0.90) and NSTEMI (hazard ratio, 0.76; 95% confidence interval, 0.65 to 0.89) (P for interactionϭ0.22). These data suggest that the relative mortality among patients managed invasively for STEMI and NSTEMI is time dependent, with NSTEMI imparting a delayed but substantial enhancement of mortality risk; moreover, early revascularization may improve very late survival to a similar extent for both infarct types. In clinical investigations of early revascularization among patients with NSTEMI, extended follow-up may therefore be necessary to demonstrate treatment benefit. See p 3110.
Living Near Major Traffic Roads and Risk of Deep Vein Thrombosis
Venous thromboembolism is the third most common cardiovascular disease behind acute coronary syndromes and stroke. Exposure to particulate air pollution has been associated with increased risk of arterial cardiovascular disease, but only a few data are available on venous thrombosis. Because road traffic is a major source of exposure to particulate pollution, individuals living closer to major traffic roads might be at higher risk for air pollution effects. In a study of 663 patients with deep vein thrombosis (DVT) of the lower limbs and 859 age-matched controls from Lombardy, Italy, we found that individuals living near major traffic roads had a higher risk of DVT than those living farther away. Using multivariable modeling adjusting for multiple clinical and environmental covariates, we estimated that an individual living at an index distance of 3 meters of distance from a major traffic road had a 47% increase in DVT risk compared with an individual living at a reference distance of 245 meters. The increase in DVT risk was approximately linear over the observed distance range (from 718 to 0 meters) and was not modified after adjusting for background levels of particulate matter measured in the areas of residence of the study participants. These findings provide novel evidence that living near major traffic roads is associated with increased risk of DVT. See p 3118.
Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms
Abdominal aneurysms pose a considerable health burden and are the third-commonest cause of sudden death in the elderly. Many countries have now instituted health screening programs that incorporate an abdominal ultrasound. Screening for aneurysms reveals a prevalence of 5% in men Ͼ65 years of age. The vast majority of these aneurysms are below the threshold for surgical repair. At present, there is no proven medical therapy that will retard the expansion of abdominal aneurysms or reduce the incidence of fatal rupture. Targeted pharmacotherapy is clearly needed to offer effective management of patients with aneurysms. The pathological processes underpinning aneurysm expansion include inflammation, proteolysis, apoptosis, and angiogenesis, which must be targeted in potential medical strategies to retard the aneurysmal process. Previous studies have suggested that agents with pleiotropic actions may be the most effective, especially if directed toward early targets in the signaling cascade. The present study has suggested that activation of peroxisome proliferator-activated receptor-␥, through the thiazolidinedione rosiglitazone, is able to reduce aneurysm expansion and rupture in a well-validated experimental model. Although the exact mechanism of action requires further investigation, the findings are encouraging and stimulate consideration for a translational study. A proof-of-concept study in a small number of patients appears justified to establish compliance and safety, with a larger study required to prove efficacy in reducing the expansion of small abdominal aortic aneurysms. See p 3125.
